Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wei

Showing results (341-350 of 393) with videos related to

Pageof 40
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE studyH S Rugo, J O'Shaughnessy, F Boyle, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|October 18, 2015
Association of Resting Heart Rate with Infrarenal Aortic Diameter: A Cross Sectional Study in Chinese Hypertensive AdultsR Wei, L S Liu, L W Wang, et al.
Human Molecular Genetics|January 18, 2014
A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's diseaseMarianne R Smith, Adeela Syed, Tamas Lukacsovich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Nature Cancer|February 5, 2022
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulationLan Wu, Edward Seung, Ling Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
Nature Communications|June 22, 2023
Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infectionsWanwisa Promsote, Ling Xu, Jason Hataye, et al.
Science (New York, N.Y.)|September 22, 2017
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaquesLing Xu, Amarendra Pegu, Ercole Rao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern ChinaM F Ji, W Sheng, W M Cheng, et al.
Cell Reports|January 5, 2022
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu, Ling Xu, Megan E DeMouth, et al.
Pageof 40

Showing results (341-350 of 393) with videos related to

Sort By:
Pageof 40
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE studyH S Rugo, J O'Shaughnessy, F Boyle, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|October 18, 2015
Association of Resting Heart Rate with Infrarenal Aortic Diameter: A Cross Sectional Study in Chinese Hypertensive AdultsR Wei, L S Liu, L W Wang, et al.
Human Molecular Genetics|January 18, 2014
A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's diseaseMarianne R Smith, Adeela Syed, Tamas Lukacsovich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Nature Cancer|February 5, 2022
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulationLan Wu, Edward Seung, Ling Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
Nature Communications|June 22, 2023
Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infectionsWanwisa Promsote, Ling Xu, Jason Hataye, et al.
Science (New York, N.Y.)|September 22, 2017
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaquesLing Xu, Amarendra Pegu, Ercole Rao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2019
Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern ChinaM F Ji, W Sheng, W M Cheng, et al.
Cell Reports|January 5, 2022
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu, Ling Xu, Megan E DeMouth, et al.
Pageof 40